Matt Hoffman

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic exposure.

Twice-daily clobetasol 0.05% cleared cells in 26.5% vs 8.6% of patients and pain in 75.1% vs 32.4% after cataract surgery, with no added endothelial cell loss.

Initial phaco for angle-closure glaucoma climbed to 48.4% in adults 50 and older, while surveys and IRIS data show shifting trabeculectomy and JOAG surgical patterns.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.

Noguchi FS formula error was 0.280 D in 486 eyes, LAL piggyback cut residual cylinder to 0.1 D, and Yamane and Gore-Tex fixation showed distinct complication profiles.

In the phase 3 RESTORE-3 trial of 116 Chinese participants, the anti-IGF-1R antibody produced a 60.4% proptosis response rate vs 23.5% with placebo at week 24.

Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease.

Nimesh A. Patel, MD, explains why myopia-related retinal detachments are appearing earlier and how routine exams can catch them.

Nimesh A. Patel, MD, discusses compounded low-dose atropine and SYD-101 ahead of an October 30 FDA advisory committee meeting.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.

Wnt modulators, sustained-release TKIs, and topical steroids are in phase 3 trials for DME, offering alternatives to anti-VEGF injections.

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.